Cargando…
Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab
INTRODUCTION: Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity. CASE PRESENTATION: We present the case of a patient with metastatic mucinous tubular and spind...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413205/ https://www.ncbi.nlm.nih.gov/pubmed/34497997 http://dx.doi.org/10.1002/iju5.12342 |
_version_ | 1783747612055175168 |
---|---|
author | Fuchizawa, Hirotaka Kijima, Toshiki Takada‐Owada, Atsuko Nagashima, Yoji Okazaki, Akihito Yokoyama, Megumi Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao |
author_facet | Fuchizawa, Hirotaka Kijima, Toshiki Takada‐Owada, Atsuko Nagashima, Yoji Okazaki, Akihito Yokoyama, Megumi Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao |
author_sort | Fuchizawa, Hirotaka |
collection | PubMed |
description | INTRODUCTION: Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity. CASE PRESENTATION: We present the case of a patient with metastatic mucinous tubular and spindle cell carcinoma who achieved durable complete remission of multiple osseous metastases after undergoing cytoreductive nephrectomy followed by combination immunotherapy (ipilimumab plus nivolumab). Immunohistochemical analyses of the primary tumor revealed the presence of the tumor‐infiltrating immune cells, including activated CD8(+) T cells and PD‐L1 expression, suggesting an immunologically hot tumor. CONCLUSION: Combination immunotherapy was a viable treatment option for this disease. Immunohistochemical analyses of the tumor‐infiltrating immune cells predicted the efficacy of immune checkpoint inhibitors against rare renal cancers. |
format | Online Article Text |
id | pubmed-8413205 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84132052021-09-07 Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab Fuchizawa, Hirotaka Kijima, Toshiki Takada‐Owada, Atsuko Nagashima, Yoji Okazaki, Akihito Yokoyama, Megumi Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao IJU Case Rep Case Reports INTRODUCTION: Mucinous tubular and spindle cell carcinoma is a rare subtype of renal cell carcinoma. Little is known regarding the efficacy of systemic therapy on its metastatic form because of its rarity. CASE PRESENTATION: We present the case of a patient with metastatic mucinous tubular and spindle cell carcinoma who achieved durable complete remission of multiple osseous metastases after undergoing cytoreductive nephrectomy followed by combination immunotherapy (ipilimumab plus nivolumab). Immunohistochemical analyses of the primary tumor revealed the presence of the tumor‐infiltrating immune cells, including activated CD8(+) T cells and PD‐L1 expression, suggesting an immunologically hot tumor. CONCLUSION: Combination immunotherapy was a viable treatment option for this disease. Immunohistochemical analyses of the tumor‐infiltrating immune cells predicted the efficacy of immune checkpoint inhibitors against rare renal cancers. John Wiley and Sons Inc. 2021-06-29 /pmc/articles/PMC8413205/ /pubmed/34497997 http://dx.doi.org/10.1002/iju5.12342 Text en © 2021 The Authors. IJU Case Reports published by John Wiley & Sons Australia, Ltd on behalf of the Japanese Urological Association https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Case Reports Fuchizawa, Hirotaka Kijima, Toshiki Takada‐Owada, Atsuko Nagashima, Yoji Okazaki, Akihito Yokoyama, Megumi Nishihara, Daisaku Ishida, Kazuyuki Kamai, Takao Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab |
title | Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab |
title_full | Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab |
title_fullStr | Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab |
title_full_unstemmed | Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab |
title_short | Metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab |
title_sort | metastatic mucinous tubular and spindle cell carcinoma of the kidney responding to nivolumab plus ipilimumab |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8413205/ https://www.ncbi.nlm.nih.gov/pubmed/34497997 http://dx.doi.org/10.1002/iju5.12342 |
work_keys_str_mv | AT fuchizawahirotaka metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab AT kijimatoshiki metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab AT takadaowadaatsuko metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab AT nagashimayoji metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab AT okazakiakihito metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab AT yokoyamamegumi metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab AT nishiharadaisaku metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab AT ishidakazuyuki metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab AT kamaitakao metastaticmucinoustubularandspindlecellcarcinomaofthekidneyrespondingtonivolumabplusipilimumab |